JP2008503533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503533A5 JP2008503533A5 JP2007517196A JP2007517196A JP2008503533A5 JP 2008503533 A5 JP2008503533 A5 JP 2008503533A5 JP 2007517196 A JP2007517196 A JP 2007517196A JP 2007517196 A JP2007517196 A JP 2007517196A JP 2008503533 A5 JP2008503533 A5 JP 2008503533A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lower alkyl
- composition according
- tremor
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 206010044565 Tremor Diseases 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- -1 methylpyrrolyl Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims 1
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 claims 1
- 206010008072 Cerebellar syndrome Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 206010069099 Holmes tremor Diseases 0.000 claims 1
- 206010022520 Intention tremor Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010072377 Psychogenic tremor Diseases 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 208000002343 primary orthostatic tremor Diseases 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 **(CCC(*)=O)C(N*)=O Chemical compound **(CCC(*)=O)C(N*)=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58208404P | 2004-06-24 | 2004-06-24 | |
| US60/582,084 | 2004-06-24 | ||
| PCT/EP2005/006750 WO2006000397A1 (en) | 2004-06-24 | 2005-06-22 | Novel use of peptide compounds for treating essential tremor and other tremor syndromes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008503533A JP2008503533A (ja) | 2008-02-07 |
| JP2008503533A5 true JP2008503533A5 (enExample) | 2008-04-17 |
| JP5038892B2 JP5038892B2 (ja) | 2012-10-03 |
Family
ID=34970895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007517196A Expired - Fee Related JP5038892B2 (ja) | 2004-06-24 | 2005-06-22 | 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7427601B2 (enExample) |
| EP (1) | EP1758606A1 (enExample) |
| JP (1) | JP5038892B2 (enExample) |
| KR (1) | KR20070034477A (enExample) |
| CN (1) | CN1964733B (enExample) |
| AR (1) | AR049940A1 (enExample) |
| AU (1) | AU2005256468B2 (enExample) |
| BR (1) | BRPI0512622A (enExample) |
| CA (1) | CA2566301C (enExample) |
| EA (1) | EA013592B1 (enExample) |
| IL (1) | IL179732A0 (enExample) |
| MX (1) | MXPA06015010A (enExample) |
| MY (1) | MY146509A (enExample) |
| NO (1) | NO20070423L (enExample) |
| NZ (1) | NZ551207A (enExample) |
| TW (1) | TWI361693B (enExample) |
| UA (1) | UA88166C2 (enExample) |
| WO (1) | WO2006000397A1 (enExample) |
| ZA (1) | ZA200609021B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1243262B1 (en) * | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| DE60100055T2 (de) * | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| WO2005053667A1 (en) * | 2003-12-02 | 2005-06-16 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| KR20070007931A (ko) * | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| WO2006021412A2 (en) * | 2004-08-27 | 2006-03-02 | Schwarz Pharma Ag | Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US7902401B2 (en) * | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| US8735356B2 (en) | 2006-06-15 | 2014-05-27 | Ucb Pharma Gmbh | Anticonvulsant combination therapy |
| WO2008070994A1 (en) * | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| US7747551B2 (en) * | 2007-02-21 | 2010-06-29 | Neurovista Corporation | Reduction of classification error rates and monitoring system using an artificial class |
| WO2011037833A2 (en) * | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| US20110281808A1 (en) * | 2010-05-14 | 2011-11-17 | Allmax Nutrition Inc. | Composition and Method for Increasing Pre Workout Thermogenics |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| JP6027539B2 (ja) | 2010-12-02 | 2016-11-16 | ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ | ラコサミドの１日１回投与用製剤 |
| EP4233861A3 (en) * | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378729A (en) | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| WO2002013766A2 (en) * | 2000-08-17 | 2002-02-21 | Teva Pharmaceutical Industries, Ltd. | Valproic acid derivatives for the treatment of pain |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| EP1695703B1 (en) * | 2000-08-25 | 2010-08-11 | Research Corporation Technologies, Inc. | Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis |
| ATE397584T1 (de) | 2000-11-21 | 2008-06-15 | Ucb Pharma Sa | N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| JP2004523557A (ja) * | 2001-02-23 | 2004-08-05 | ジョンズ・ホプキンス・ユニバーシティ | チック、振せん、および関連疾患の治療 |
| EP1243262B1 (en) | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| DE60100055T2 (de) | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6828462B2 (en) * | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| EP1539145A2 (en) * | 2002-09-13 | 2005-06-15 | Eisai Co., Ltd. | Method of treating tremors |
| US7485622B2 (en) | 2002-11-18 | 2009-02-03 | Bioprospecting Nb Inc. | Paralytic peptide for use in neuromuscular therapy |
| US20050227961A1 (en) | 2004-04-08 | 2005-10-13 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| EP1604654A1 (en) | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
-
2005
- 2005-06-10 US US11/149,181 patent/US7427601B2/en not_active Expired - Fee Related
- 2005-06-22 WO PCT/EP2005/006750 patent/WO2006000397A1/en not_active Ceased
- 2005-06-22 CN CN2005800185331A patent/CN1964733B/zh not_active Expired - Fee Related
- 2005-06-22 NZ NZ551207A patent/NZ551207A/en not_active IP Right Cessation
- 2005-06-22 EA EA200700108A patent/EA013592B1/ru not_active IP Right Cessation
- 2005-06-22 AU AU2005256468A patent/AU2005256468B2/en not_active Ceased
- 2005-06-22 BR BRPI0512622-3A patent/BRPI0512622A/pt not_active IP Right Cessation
- 2005-06-22 KR KR1020067025264A patent/KR20070034477A/ko not_active Abandoned
- 2005-06-22 CA CA2566301A patent/CA2566301C/en not_active Expired - Fee Related
- 2005-06-22 EP EP05753740A patent/EP1758606A1/en not_active Withdrawn
- 2005-06-22 JP JP2007517196A patent/JP5038892B2/ja not_active Expired - Fee Related
- 2005-06-22 UA UAA200613472A patent/UA88166C2/ru unknown
- 2005-06-22 MX MXPA06015010A patent/MXPA06015010A/es active IP Right Grant
- 2005-06-23 TW TW094121028A patent/TWI361693B/zh not_active IP Right Cessation
- 2005-06-24 AR ARP050102604A patent/AR049940A1/es not_active Application Discontinuation
- 2005-06-24 MY MYPI20052909A patent/MY146509A/en unknown
-
2006
- 2006-10-30 ZA ZA200609021A patent/ZA200609021B/xx unknown
- 2006-11-30 IL IL179732A patent/IL179732A0/en unknown
-
2007
- 2007-01-23 NO NO20070423A patent/NO20070423L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501760A5 (enExample) | ||
| JP2008501753A5 (enExample) | ||
| JP2007530493A5 (enExample) | ||
| JP2007532607A5 (enExample) | ||
| CA2566301A1 (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
| JP2010530431A5 (enExample) | ||
| JP2015503540A5 (enExample) | ||
| JP2006507326A5 (enExample) | ||
| JP2008510758A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| BRPI0912607A2 (pt) | medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete | |
| ES2704229T3 (es) | Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia | |
| JP2018509419A5 (enExample) | ||
| JP2009521473A5 (enExample) | ||
| JP2014530842A5 (enExample) | ||
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| WO2021201201A1 (ja) | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 | |
| JP2016027024A5 (enExample) | ||
| JP2010527354A5 (enExample) | ||
| CN101605541A (zh) | 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮 | |
| JP5547487B2 (ja) | 抗癌化合物の投与方法 | |
| WO2013009812A1 (en) | Methods of treatment | |
| CA2420537A1 (en) | A composition for treatment of parkinson's disease |